Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice COMMENT

被引：117

作者：

Wharton, Sean ^{[1
,2
]}

Davies, Melanie ^{[3
,4
]}

Dicker, Dror ^{[5
,6
,7
]}

Lingvay, Ildiko ^{[8
,9
]}

Mosenzon, Ofri ^{[10
,11
]}

Rubino, Domenica M. ^{[12
]}

Pedersen, Sue D. ^{[13
]}

机构：

[1] York Univ, McMaster Univ, Toronto, ON, Canada

[2] Wharton Weight Management Clin, Toronto, ON, Canada

[3] Univ Leicester, Diabet Res Ctr, Leicester, Leics, England

[4] NIHR Leicester Biomed Res Ctr, Leicester, Leics, England

[5] Rabin Med Ctr, Hasharon Hosp, Internal Med Dept, Petah Tiqwa, Israel

[6] Rabin Med Ctr, Hasharon Hosp, Obes Clin, Petah Tiqwa, Israel

[7] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel

[8] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med Endocrinol, Dallas, TX 75390 USA

[9] Univ Texas Southwestern Med Ctr Dallas, Dept Populat & Data Sci, Dallas, TX 75390 USA

[10] Hebrew Univ Jerusalem, Hadassah Med Ctr, Dept Endocrinol & Metab, DiabetesUnit, Jerusalem, Israel

[11] Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel

[12] Washington Ctr Weight Management & Res, Arlington, VA USA

[13] C ENDO Diabet & Endocrinol Clin Calgary, Calgary, AB, Canada

来源：

POSTGRADUATE MEDICINE | 2022年 / 134卷 / 01期

关键词：

TYPE-2; LIRAGLUTIDE; SEMAGLUTIDE; ADULTS; MG;

D O I：

10.1080/00325481.2021.2002616

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are well established in clinical practice for the treatment of type 2 diabetes, and are approved and recommended for weight management in overweight or obesity. Gastrointestinal side effects are well known as the most common adverse effects of these agents and represent a potential barrier for use, particularly at higher doses. Drawing on both published evidence and our collective clinical experience, we aim to guide practitioners through managing these side effects with a view to optimizing therapeutic outcomes with GLP-1RAs.

引用

页码：14 / 19

页数：6

共 24 条

[1]

Almandoz Jaime P, 2020, Clin Diabetes, V38, P390, DOI [10.2337/cd19-0100, 10.2337/cd19-0100]

[2]

[Anonymous], 2016, Endocr Pract, V22, P1

[3] Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials [J].

Bettge, Karolin ;

Kahle, Melanie ;

Abd El Aziz, Mirna S. ;

Meier, Juris J. ;

Nauck, Michael A. .

DIABETES OBESITY & METABOLISM, 2017, 19 (03) :336-347

[4] Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, doubleblind, double-dummy, placebo-controlled, phase 3 trial [J].

Davies, Melanie ;

Faerch, Louise ;

Jeppesen, Ole K. ;

Pakseresht, Arash ;

Pedersen, Sue D. ;

Perreault, Leigh ;

Rosenstock, Julio ;

Shimomura, Iichiro ;

Viljoen, Adie ;

Wadden, Thomas A. ;

Lingvay, Ildiko .

LANCET, 2021, 397 (10278) :971-984

[5] Effectiveness and Persistence with Liraglutide Among Patients with Type 2 Diabetes in Routine Clinical Practice-EVIDENCE: A Prospective, 2-Year Follow-Up, Observational, Post-Marketing Study [J].

Gautier, Jean-Francois ;

Martinez, Luc ;

Penfornis, Alfred ;

Eschwege, Eveline ;

Charpentier, Guillaume ;

Huret, Benoit ;

Madani, Suliya ;

Gourdy, Pierre .

ADVANCES IN THERAPY, 2015, 32 (09) :838-853

[6] Obstetrician-Gynecologists' Strategies for Patient Initiation and Maintenance of Antiobesity Treatment with Glucagon-Like Peptide-1 Receptor Agonists [J].

Gill, Lisa ;

Mackey, Suzanne .

JOURNAL OF WOMENS HEALTH, 2021, 30 (07) :1016-1027

[7] Switching between GLP-1 receptor agonists in clinical practice: Expert consensus and practical guidance [J].

Jain, Akshay B. ;

Ali, Amar ;

Gorgojo Martinez, Juan J. ;

Hramiak, Irene ;

Kavia, Ketan ;

Madsbad, Sten ;

Potier, Louis ;

Prohaska, Ben D. ;

Strong, Jodi L. ;

Vilsboll, Tina .

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2021, 75 (02)

[8] GLP-1 and weight loss: unraveling the diverse neural circuitry [J].

Kanoski, Scott E. ;

Hayes, Matthew R. ;

Skibicka, Karolina P. .

AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2016, 310 (10) :R885-R895

[9] GLP-1 receptor agonists in the treatment of type 2 diabetes-state-of-the-art [J].

Nauck, Michael A. ;

Quast, Daniel R. ;

Wefers, Jakob ;

Meier, Juris J. .

MOLECULAR METABOLISM, 2020, 46

[10] Are all GLP-1 agonists equal in the treatment of type 2 diabetes? [J].

Nauck, Michael A. ;

Meier, Juris J. .

EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2019, 181 (06) :R211-R234

← 1 2 3 →